What is nChroma Bio?
nChroma Bio is a pioneering biotechnology company dedicated to developing in vivo targeted genetic medicine. The company aims to address a wide array of diseases by bringing innovative cures to patients through advanced genetic therapies. Its focus on in vivo treatments signifies a commitment to precision medicine, potentially offering less invasive and more effective therapeutic options compared to traditional ex vivo approaches. The company's work is positioned at the forefront of genetic medicine innovation, seeking to unlock new possibilities for treating complex conditions.
How much funding has nChroma Bio raised?
nChroma Bio has raised a total of $75M across 1 funding round:
Other Financing Round
$75M
Other Financing Round (2024): $75M with participation from Atlas Venture, ARCH Venture Partners, and Cormorant Asset Management
Key Investors in nChroma Bio
Atlas Venture
Atlas Venture is a pioneering early-stage venture capital firm focused on creating and building breakthrough biotechnology companies that translate cutting-edge science into life-changing medicines. The firm partners with exceptional life science entrepreneurs to support the launch and growth of innovative biotech startups.
ARCH Venture Partners
ARCH Venture Partners is a leading earlystage venture capital firm that creates and invests in life sciences and advanced technology companies, often cofounding startups with scientists and entrepreneurs to commercialize innovations from universities, corporate R&D groups, and national laboratories.
Cormorant Asset Management
Founded in 2013, Cormorant Asset Management ('Cormorant') is a prominent life sciences investment firm with over $3B of assets under management as of June 2021. Cormorant is driven by a deep focus on fundamental scientific principles and provides financial resources to support the most innovative and promising publicly traded and private companies in biotech and allied sectors.
What's next for nChroma Bio?
With the recent major strategic investment, nChroma Bio is poised for accelerated growth and the advancement of its therapeutic pipeline. This substantial backing, alongside its total funding, suggests a strong market validation and confidence in the company's technology and leadership. The strategic nature of the recent financing indicates potential collaborations or deeper partnerships that could expedite the development and commercialization of its genetic medicine platforms. Investors like Atlas Venture, ARCH Venture Partners, and Cormorant Asset Management, known for their focus on early-stage and growth-stage biotech ventures, are likely to provide not only capital but also critical strategic guidance and operational support as nChroma Bio navigates the complex path from development to patient delivery.
See full nChroma Bio company page
